

April 30, 2026

<p>To The Secretary, Listing Department, BSE Limited, 1st Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001.</p> <p>Scrip Code: 540975</p>	<p>To The Manager, Listing Department, The National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai 400051.</p> <p>Scrip Symbol: ASTERDM</p>
--	--

Dear Sir/Madam,

Sub: Press release on the financial results for the quarter and year ended March 31, 2026

Re: Regulation 30 read-with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, please find enclosed press release being issued today in relation to the annual audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2026.

This is for your information and records.

Thank you

For **Aster DM Healthcare Limited**

Hemish Purushottam

Company Secretary and Compliance Officer

M. No. A24331

Aster DM Healthcare Limited – Registered Office

No 7-1-450/20, Plot No-04, Mythri Vihar,
Sanjeev Reddy Nagar, Hyderabad, Ameerpet,
Telangana, India - 500038

Aster DM Healthcare Limited – Corporate Office

Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1,
Mission Road, Sampangi Rama Nagar, Bengaluru,
Karnataka, India - 560027

Aster DM Healthcare Q4 FY26 Results:

**Aster DM Healthcare delivers robust Q4 FY26 performance;
Q4 FY26 Revenues up by 18% YoY to INR 1,182 Cr; Op. EBITDA (ex-Kasargod) up by 31%
Aster and Quality Care India Ltd (Combined Proforma) delivers strong performance;
Q4 FY26 Revenues up by 18% to INR 2,361 Cr; Op. EBITDA up by 25%**

Key Financial Highlights

Aster DM Healthcare for Q4 FY26:

- Revenue for Q4 FY26 grew 18% YoY to INR 1,182 Cr
- Operating EBITDA (ex-Kasargod) grew 31% YoY to INR 253 Cr in Q4 FY26
- Operating EBITDA Margins (ex-Kasargod) stood at 21.7% in Q4 FY26 Vs. 19.3% in Q4 FY25
- Normalised PAT¹ (ex-Kasargod) grew 45% YoY to INR 153 Cr In Q4 FY26

Aster + QCIL (Combined Proforma) Performance for Q4 FY26

- Proforma Revenue for Q4 FY26 grew by 18% to INR 2,361 Cr
- Proforma Operating EBITDA grew by 25% to INR 517 Cr
- Proforma Operating EBITDA margin stood at 21.9%
- The merger proposal received overwhelming shareholder approval, with 96.68% of total votes cast in favor.

Bengaluru, April 30, 2026: Aster DM Healthcare, one of the leading integrated healthcare service providers in India, today announced its financial results for the quarter ended March 31, 2026.

Commenting on the performance for Q4 FY26, Dr. Azad Moopen, Founder and Chairman, Aster DM Healthcare, said:

"We are very pleased that the merger of Aster DM Healthcare and Quality Care India Limited (QCIL), in partnership with Blackstone, is progressing towards completion in Q1 FY 2026–27. The overwhelming shareholder support, with 96.68% votes in favour, reflects strong confidence in our vision of building a scaled and integrated healthcare platform. On a proforma basis, Q4 FY26 revenues grew 18% YoY to INR 2,361 Cr, while operating EBITDA increased 25% YoY to INR 517 Cr, supported by strong growth in patient volumes, and continued margin expansion.

The combined entity will have a capacity of over 10,623 beds across 28 cities, with an additional pipeline of around 4,445 beds, providing clear visibility to exceed 15,500 beds in the near term, thus . This positions the platform to become one of the top three healthcare providers in India."

On Q4 FY26 performance of Aster DM Healthcare Dr. Moopen added, "Our performance this quarter reflects consistent execution, with revenues growing 18% YoY to INR 1,182 Cr. Excluding the impact of the newly commissioned Kasargod facility, operating EBITDA grew 31% YoY, with margins improving to 21.7%, driven by operating leverage and disciplined cost management."

¹Post NCI

India Performance Highlights

Overall Business: Strong YoY growth in Revenue and Operating EBITDA led by robust performance across Core Hospital & Clinics as well as Labs businesses, despite macro headwinds

- ARPP IP rose 9% YoY to INR 1,25,234 in Q4 FY26
- Total patient volume grew by 15% YoY with IP volume growing by 7% YoY and OP volume growing by 15% YoY in Q4 FY26.
- Significant growth in MVT revenue by 41% YoY in Q4 FY26, led by 51% YoY growth in Kerala MVT revenue
- Healthy growth in Cardiac and Oncology revenues by 25% and 23% YoY respectively, with contributions at 15% and 11% in Q4 FY26, reflecting continued strength in specialty mix
- Aster Labs revenue grew by 18% YoY in Q4 FY26 and Op. EBITDA grew by 181% YoY with margins improved to 14.7% in Q4 FY26 as compared to 6.2% in Q4 FY25

Core Hospital Business

- Core hospitals & clinics business delivered an Op. EBITDA margin of 23.1% in Q4 FY26 (24.3% Ex-Kasargod)
- Matured hospital Operating EBITDA margins stood at 26.2% in Q4 FY26 (22.9% in Q4 FY25)
- Aster Medcity revenue grew by 16% YoY and Op. EBITDA grew by 26% YoY in Q4 FY26 with margins at 32.5%
- Aster MIMS Calicut revenue grew by 21% YoY and Op. EBITDA grew by 41% YoY in Q4 FY26 with margin at 23.8%
- Aster Whitefield revenue grew by 15% YoY and Op. EBITDA grew by 38% YoY in Q4 FY26

Cluster-wise Performance:

- Kerala total patient volume increased by 20% YoY delivering 21% YoY revenue growth
- Andhra & Telangana revenue grew 30% YoY, supported by 20 % YoY increase in total patient volume
- Kerala Cluster Operating EBITDA grew by 27% YoY (35% ex-Kasargod) with margins at 23.5% (25.6% ex. Kasargod) in Q4 FY26 from
- Karnataka & Maharashtra Operating EBITDA grew by 25% YoY with margin at 24.5% in Q4 FY26
- Andhra & Telangana cluster Operating EBITDA grew by 113 % YoY with margin at 18.3% in Q4 FY26

Update on Merger

Post receipt of the shareholders' approval, the Company had completed the preferential allotment of ~3.6% stake to Blackstone and TPG in lieu of initial acquisition of 5.0% stake in Quality Care India Ltd. Further to the preferential allotment, the company received CCI approval followed by the receipt of a no-objection letter from the Stock Exchanges for the merger. During the quarter, the company has also received shareholders and creditors' approval in favor of the merger.

The closing of transaction is pending fulfilment of regulatory and compliance requirements, including the receipt of NCLT order. The transaction is expected to be completed by Q1 FY27.

¹Post NCI

QCIL Q4 FY26 Performance

QCIL reported a notable Q4 FY26 performance, with revenue rising 18% YoY to INR 1,178 Cr. Operating EBITDA grew 23% YoY to INR 272 Cr, with margins at 23.1%, reflecting sustained efficiency improvements and disciplined cost management. ALOS improved to 3.94 days, indicating enhanced clinical protocols and better patient throughput.

Combined Proforma Performance for Q4 FY26

The combined entity (Aster and QCIL), with a network of over 10,620+ beds across 39 hospitals in 28 cities, reported a strong performance this quarter on a combined basis. Revenue grew 18% to INR 2,361 Cr, while Operating EBITDA increased 25% to INR 517 Cr (ex-Kasaragod up by 27% to INR 526 Cr). EBITDA margins remained healthy at 21.9% (ex-Kasaragod 22.4%), with ROCE at 21.2% (ex-Kasaragod 21.7%), highlighting the platform’s scale, operational strength, and growth potential.

About Aster DM Healthcare, India

Aster DM Healthcare Limited is one of the largest healthcare service providers operating in India with a strong presence across primary, secondary, tertiary, and quaternary healthcare through 20 hospitals with 5,449 beds, 10 clinics, 203 pharmacies (Operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster), and 304 labs and patient experience centers across 5 states in India, delivering a simple yet strong promise to different stakeholders: “We’ll Treat You Well.”

For more information about us, please visit www.asterdmhealthcare.com or contact:

Get in touch: Aster DM Healthcare	
Corporate Communications	Investor Relations
Sreehari Nair Email: sreehari.nair@asterdmhealthcare.in Mob: +91 9606077445	Puneet Maheshwari Email: puneet.maheshwari@asterdmhealthcare.in Mob: + 91 9920486380
	Himani Singla Email: himani.singla@asterdmhealthcare.in Mob: +91 9569926021

DISCLAIMER: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Aster DM Healthcare will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. QCIL Numbers are Indicative and subject to statutory audit adjustments. Proforma numbers for merger entity are also subject to finalization and audit of the merged accounts. Actual amounts, losses or impact on net profit could materially differ from those that have been estimated. In addition, other factors that could cause actual results to differ materially from those estimated include harmonization of accounting policies and practices.

¹Post NCI